Emmanuelle Schuler

Chief Executive Officer, Stellanova Therapeutics

Professional Overview
Emmanuelle Schuler is an accomplished biopharmaceutical executive with a strong track record of leading innovative companies in the life sciences industry. As the Chief Executive Officer of Stellanova Therapeutics, she leverages her extensive expertise in drug development, strategic planning, and operational excellence to drive the company's growth and impact.

Experience Summary

Current Role
As the Chief Executive Officer of Stellanova Therapeutics since January 2021, Emmanuelle is responsible for setting the strategic vision, overseeing all business operations, and positioning the company as a leader in the development of cutting-edge therapeutic solutions. Under her guidance, Stellanova has made significant advancements in its pipeline of novel drug candidates, with several compounds progressing through clinical trials.

Career Progression
Prior to joining Stellanova Therapeutics, Emmanuelle held various leadership roles within the biopharmaceutical industry, where she consistently demonstrated her ability to drive innovation and deliver exceptional results. Her previous experience includes serving as the Vice President of Research and Development at a prominent global pharmaceutical company, where she led cross-functional teams in the successful development and commercialization of several blockbuster drugs.

Academic Background
Emmanuelle holds a Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, where her research focused on the development of novel drug delivery systems. She has also completed executive leadership programs at Harvard Business School and the Massachusetts Institute of Technology, further strengthening her strategic and operational expertise.

Areas of Expertise
Emmanuelle's areas of expertise span the full spectrum of biopharmaceutical operations, including drug discovery, clinical development, regulatory affairs, and commercial strategy. She is particularly adept at identifying and capitalizing on emerging industry trends, fostering collaborative partnerships, and building high-performing teams that drive transformative change.

Professional Impact
Throughout her career, Emmanuelle has been recognized for her significant contributions to the life sciences industry. She has led the development and successful commercialization of multiple innovative therapies that have improved the lives of patients worldwide. Emmanuelle is also an active participant in industry associations and thought leadership initiatives, sharing her insights and best practices with the broader biopharmaceutical community.

Conclusion
With her exceptional leadership skills, deep industry knowledge, and unwavering commitment to innovation, Emmanuelle Schuler is well-positioned to guide Stellanova Therapeutics through its next phase of growth and impact. As the Chief Executive Officer, she is dedicated to advancing the company's pipeline of promising drug candidates and establishing Stellanova as a leading force in the biopharmaceutical industry.